ReviewChemical research in toxicology2011
Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action.
Review in Chemical research in toxicology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 2 syntheses or guidelines pooled it, 513 citations in OpenAlex.
- The role of nutrition in harnessing the immune system: a potential approach to prevent cancer.Medical oncology (Northwood, London, England) · 2022Pooled it
- Does air pollution play a role in infertility?: a systematic review.Environmental health : a global access science source · 2017Pooled it
- Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.JCI insight · 2020Trial
- Sakuranetin modulates estrogen receptor signaling in breast cancer cells.Journal of functional foods · 2026Article
- Association between urinary bisphenol levels and metabolic syndrome in Korean adults: a cross-sectional study using the fourth Korean National Environmental Health Survey.Annals of occupational and environmental medicine · 2026Article
- The Role of Sex Hormone Receptors in the Squamous Cell Carcinoma of the Uterine Ectocervix: A Review and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- AhR as a Common Denominator in Immunity and Inflammation in Chronic Lung Diseases: Molecular and Clinical Insights.Diseases (Basel, Switzerland) · 2026Review
- Implications of Endocrine-Disrupting Chemicals for Human Health and Effective Methods for Prevention and Reduction.Toxics · 2026Review
- Personal Care Products and Incident Hypertension: Prospective Cohort Study of U.S. Women.medRxiv : the preprint server for health sciences · 2026Article
- Environmental estrogens and animal reproductive health: mechanisms, biomarkers, and intervention approaches.Journal of animal science and biotechnology · 2026Review
- Multimodal Cross-Attentive Graph-Based Framework for Predicting In Vivo Endocrine Disruptors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Molecular networking, conformal predictions and revised fingerprint-based models for discovering endocrine disruptors in mixtures.Analytical and bioanalytical chemistry · 2026Article
- Environmental Pollutants and Food Allergy: From Traditional Triggers to Emerging Hazards.Clinical reviews in allergy & immunology · 2026Review
- When Estrogen Signaling Refuses to Die: Receptor Rewiring, Compartmentalization, and Endocrine Plasticity in Gynecological Cancers.International journal of molecular sciences · 2026Review
- Review
- Reproductive Impact of Natural, Synthetic and Emerging Chemicals on Wildlife and Domestic Animals.Advances in experimental medicine and biology · 2026Review
- Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancer.NPJ breast cancer · 2025Review
- Progesterone receptor isoform modulation via enhancer activation regulates progesterone signaling in endometrial stromal cells.F&S science · 2025Article
- Molecular Biocompatibility Assessment of PETG Aligners After Processing by Laser or Milling.Materials (Basel, Switzerland) · 2025Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many endocrine disrupting chemicals (EDCs) adversely impact estrogen signaling by interacting with two estrogen receptors (ERs): ERα and ERβ. Though the receptors have similar ligand binding and DNA binding domains, ERα and ERβ have some unique properties in terms of ligand selectivity and target gene regulation. EDCs that target ER signaling can modify genomic and nongenomic ER activity through direct interactions with ERs, indirectly through transcription factors such as the aryl hydrocarbon receptor (AhR), or through modulation of metabolic enzymes that are critical for normal estrogen synthesis and metabolism. Many EDCs act through multiple mechanisms as exemplified by chemicals that bind both AhR and ER, such as 3-methylcholanthrene. Other EDCs that target ER signaling include phytoestrogens, bisphenolics, and organochlorine pesticides, and many alter normal ER signaling through multiple mechanisms. EDCs can also display tissue-selective ER agonist and antagonist activities similar to selective estrogen receptor modulators (SERMs) designed for pharmaceutical use. Thus, biological effects of EDCs need to be carefully interpreted because EDCs can act through complex tissue-selective modulation of ERs and other signaling pathways in vivo. Current requirements by the U.S. Environmental Protection Agency require some in vitro and cell-based assays to identify EDCs that target ER signaling through direct and metabolic mechanisms. Additional assays may be useful screens for identifying EDCs that act through alternative mechanisms prior to further in vivo study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.